You are here
Assertio Therapeutics Announces the Appointment of Daniel A. Peisert as Senior Vice President and Chief Financial Officer; Current CFO Phil B. Donenberg to Retire November 30, 2018
LAKE FOREST, Ill., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that Phillip B. Donenberg, Senior Vice President and Chief Financial Officer, will retire effective November 30, 2018. Replacing Mr. Donenberg will be Daniel A. Peisert, who has been appointed Senior Vice President and Chief Financial Officer. Mr. Peisert was previously serving as Senior Vice President, Business Development, for Assertio.
“In his new role, Dan brings the optimal balance of strong financial acumen, healthcare experience and market savviness,” said Arthur Higgins, President and Chief Executive Officer of Assertio. “Dan is a terrific thought partner and strategic leader and I’m confident he will continue to help us find new ways to strengthen our company, generate higher growth and enhance shareholder value. We wish Phil all the best as he pursues retirement and reflects on his successful 36-year career.”
Mr. Peisert joined Assertio as Vice President, Business Development in September 2017. Most recently he served in the position of Vice President of Concordia International Corp.’s U.S. Legacy Pharmaceuticals business where he had full P&L responsibility for the business unit. Prior to this, he was Vice President, Business Development for Concordia and was responsible for executing on the strategic M&A plan. From 2008 to 2012, Mr. Peisert was Director of Finance and Business Development for Marathon Pharmaceuticals, a privately held specialty pharmaceutical company. Prior to entering the pharmaceutical industry, he was a healthcare equity analyst and portfolio manager for Magnetar Capital and UBS O’Connor and began his career as an auditor for PricewaterhouseCoopers. Mr. Peisert holds a Bachelor of Science in Business with an emphasis on Accounting from the University of Minnesota.
About Assertio Therapeutics, Inc.
Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company’s core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. To learn more about Assertio, visit www.assertiotx.com.
Investor and Media Contact:
John B. Thomas
SVP, Investor Relations and Corporate Communications